Stromal dynamic reciprocity in cancer: Intricacies of fibroblastic-ECM interactions

Current Opinion in Cell Biology

Volumn 42, Issue , 2016, Pages 80-93

  Alexander, Jennifer ^a,b   Cukierman, Edna ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPHYSICS; CANCER ASSOCIATED FIBROBLAST; CARCINOGENESIS; CELL INTERACTION; CONNECTIVE TISSUE; DESMOPLASIA; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROMA; HOMEOSTASIS; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA; STROMAL DYNAMIC RECIPROCITY; TUMOR GROWTH; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NEOPLASMS; PATHOLOGY; STROMA CELL;

ANIMALS; CANCER-ASSOCIATED FIBROBLASTS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; STROMAL CELLS;

EID: 84969256198     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2016.05.002     Document Type: Review

References (185)

1. Langhans T. Pulsirende cavernoese Geschwulst der Miltz mit metastatischen Knoten in der Leber. Virchows Archiv 1879, 75:273-291.
2. Paget S. The distribution of secondary growths in cancer of the breast. The Lancet 1889, 133:571-573.
3. Rybinski B., Franco-Barraza J., Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 2014, 46:223-244.
4. Cammarota F., Laukkanen M.O. Mesenchymal stem/stromal cells in stromal evolution and cancer progression. Stem Cells Int 2016, 2016:4824573.
5. Tarin D. Clinical and biological implications of the tumor microenvironment. Cancer Microenviron 2012, 5:95-112.
6. Naba A., Clauser K.R., Ding H., Whittaker C.A., Carr S.A., Hynes R.O. The extracellular matrix: tools and insights for the 'omics' era. Matrix Biol 2016, 49:10-24.
7. Beacham D.A., Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005, 15:329-341.
8. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
9. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J Cell Biochem 2007, 101:887-907.
10. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression?. Histol Histopathol 2002, 17:599-621.
11. Hu M., Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008, 18:27-34.
12. Lakhani S., Bissell M. Introduction: the role of myoepithelial cells in integration of form and function in the mammary gland. J Mammary Gland Biol Neoplasia 2005, 10:197-198.
13. de Jong K.P., von Geusau B.A., Rottier C.A., Bijzet J., Limburg P.C., de Vries E.G., Fidler V., Slooff M.J. Serum response of hepatocyte growth factor, insulin-like growth factor-I, interleukin-6, and acute phase proteins in patients with colorectal liver metastases treated with partial hepatectomy or cryosurgery. J Hepatol 2001, 34:422-427.
14. Goetz J.G., Minguet S., Navarro-Lerida I.R.J.J.L., Samaniego R., Calvo E., Tello M., Osteso-Ibanez T., Pellinen T., Echarri A., et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146:148-163.
15. Provenzano P.P., Eliceiri K.W., Campbell J.M., Inman D.R., White J.G., Keely P.J. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006, 4:38.
16. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A 1975, 72:3585-3589.
17. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., Weiss S.J. Membrane type i matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114:33-45.
18. Barcellos-Hoff M.H., Ravani S.A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000, 60:1254-1260.
19. Maffini M.V., Soto A.M., Calabro J.M., Ucci A.A., Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004, 117:1495-1502.
20. Xu R., Boudreau A., Bissell M.J. Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 2009, 28:167-176.
21. Schultz G.S., Davidson J.M., Kirsner R.S., Bornstein P., Herman I.M. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 2011, 19:134-148.
22. Thorne J.T., Segal T.R., Chang S., Jorge S., Segars J.H., Leppert P.C. Dynamic reciprocity between cells and their microenvironment in reproduction. Biol Reprod 2015, 92:25.
23. Werb Z., Chin J.R. Extracellular matrix remodeling during morphogenesis. Ann N Y Acad Sci 1998, 857:110-118.
24. Nelson C.M., Bissell M.J. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2006, 22:287-309.
25. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
26. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008, 9:628-638.
27. Bissell M.J., Rizki A., Mian I.S. Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol 2003, 15:753-762.
28. Hagios C., Lochter A., Bissell M.J. Tissue architecture: the ultimate regulator of epithelial function?. Philos Trans R Soc Lond B Biol Sci 1998, 353:857-870.
29. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol 2005, 167:475-488.
30. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
31. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
32. Togo S., Shimada H., Kubota T., Moossa A.R., Hoffman R.M. Host organ specifically determines cancer progression. Cancer Res 1995, 55:681-684.
33. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002, 8:2912-2923.
34. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part II): functional impact on tumor tissue. Histol Histopathol 2002, 17:623-637.
35. Tuxhorn J.A., Ayala G.E., Rowley D.R. Reactive stroma in prostate cancer progression. J Urol 2001, 166:2472-2483.
36. Li G., Satyamoorthy K., Meier F., Berking C., Bogenrieder T., Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003, 22:3162-3171.
37. Desmouliere A., Guyot C., Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004, 48:509-517.
38. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
39. Bissell M.J., Hall H.G., Parry G. How does the extracellular matrix direct gene expression?. J Theor Biol 1982, 99:31-68.
40. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
41. Tamkun J.W., DeSimone D.W., Fonda D., Patel R.S., Buck C., Horwitz A.F., Hynes R.O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 1986, 46:271-282.
42. Berrier A.L., Yamada K.M. Cell-matrix adhesion. J Cell Physiol 2007, 213:565-573.
43. Jahed Z., Shams H., Mehrbod M., Mofrad M.R.K. Chapter Five - Mechanotransduction pathways linking the extracellular matrix to the nucleus. International Review of Cell and Molecular Biology 2014, Vol. 310:171-220. Academic Press.
44. Connor Y., Tekleab S., Nandakumar S., Walls C., Tekleab Y., Husain A., Gadish O., Sabbisetti V., Kaushik S., Sehrawat S., et al. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nat Commun 2015, 6:8671.
45. Maniotis A.J., Chen C.S., Ingber D.E. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. Proc Natl Acad Sci U S A 1997, 94:849-854.
46. Ingber D.E. Tensegrity I. Cell structure and hierarchical systems biology. J Cell Sci 2003, 116:1157-1173.
47. Ingber D.E. Tensegrity II. How structural networks influence cellular information processing networks. J Cell Sci 2003, 116:1397-1408.
48. Tadeo I., Berbegall A.P., Escudero L.M., Álvaro T., Noguera R. Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance and implications in oncology and mechanotherapy. Front Oncol 2014, 4:39.
49. Anderson A.R., Weaver A.M., Cummings P.T., Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127:905-915.
50. Desmouliere A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int 1995, 19:471-476.
51. Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discovery 2015, 5:915-919.
52. Hinz B. Myofibroblasts. Exp Eye Res 2016, 142:56-70.
53. Öhlund D., Elyada E., Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014, 211:1503-1523.
54. Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., Harrington K., Williamson P., Moeendarbary E., Charras G., et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013, 15:637-646.
55. Malek A., Bakhidze E., Noske A., Sers C., Aigner A., Schafer R., Tchernitsa O. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008, 123:348-356.
56. Witte M.B., Barbul A. General principles of wound healing. Surg Clin North Am 1997, 77:509-528.
57. Engels B., Rowley D.A., Schreiber H. Targeting stroma to treat cancers. Semin Cancer Biol 2012, 22:41-49.
58. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150.
59. Barcellos-Hoff M.H. New biological insights on the link between radiation exposure and breast cancer risk. J Mammary Gland Biol Neoplasia 2013, 18:3-13.
60. Malik R., Lelkes P.I., Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol 2015, 33:230-236.
61. McConnell J.C., O'Connell O.V., Brennan K., Weiping L., Howe M., Joseph L., Knight D., O'Cualain R., Lim Y., Leek A., et al. Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. Breast Cancer Res 2016, 18:5.
62. Jodele S., Blavier L., Yoon J.M., DeClerck Y.A. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006, 25:35-43.
63. Ohuchida K., Mizumoto K., Murakami M., Qian L.W., Sato N., Nagai E., Matsumoto K., Nakamura T., Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004, 64:3215-3222.
64. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., Dekleva E.N., Saunders T., Becerra C.P., Tattersall I.W., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25:735-747.
65. Ozdemir B.C., Pentcheva-Hoang T., Carstens J.L., Zheng X., Wu C.C., Simpson T.R., Laklai H., Sugimoto H., Kahlert C., Novitskiy S.V., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734.
66. Bauer G. Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Histol Histopathol 1996, 11:237-255.
67. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17:320-329.
68. Sadlonova A., Novak Z., Johnson M.R., Bowe D.B., Gault S.R., Page G.P., Thottassery J.V., Welch D.R., Frost A.R. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res 2005, 7:R46-R59.
69. Lang M. Infinity Pharma halts pancreatic cancer trial. Boston Business Journal 2012, USA. Journal BB (Ed.).
70. Hinz B., Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 2003, 14:538-546.
71. Montesano R., Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci U S A 1988, 85:4894-4897.
72. Hinz B., Phan S.H., Thannickal V.J., Prunotto M., Desmouliere A., Varga J., De Wever O., Mareel M., Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355.
73. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006, 5:1640-1646.
74. Park S.Y., Kim H.M., Koo J.S. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 2015, 149:727-741.
75. Yazhou C., Wenlv S., Weidong Z., Licun W. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol 2004, 25:290-295.
76. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., Giese N.A., Esposito I., Friess H., Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008, 6:1155-1161.
77. Barlow J., Yandell D., Weaver D., Casey T., Plaut K. Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Res Treat 2003, 79:149-159.
78. Kheradmand F., Werner E., Tremble P., Symons M., Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998, 280:898-902.
79. Baneyx G., Baugh L., Vogel V. Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension. Proc Natl Acad Sci U S A 2002, 99:5139-5143.
80. Feral C.C., Zijlstra A., Tkachenko E., Prager G., Gardel M.L., Slepak M., Ginsberg M.H. CD98hc (SLC3A2) participates in fibronectin matrix assembly by mediating integrin signaling. J Cell Biol 2007, 178:701-711.
81. Lambert C.A., Colige A.C., Munaut C., Lapiere C.M., Nusgens B.V. Distinct pathways in the over-expression of matrix metalloproteinases in human fibroblasts by relaxation of mechanical tension. Matrix Biol 2001, 20:397-408.
82. Farrow B., Albo D., Berger D.H. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008, 149:319-328.
83. Kuwahara K., Kinoshita H., Kuwabara Y., Nakagawa Y., Usami S., Minami T., Yamada Y., Fujiwara M., Nakao K. Myocardin-related transcription factor A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Mol Cell Biol 2010, 30:4134-4148.
84. Crider B.J., Risinger G.M., Haaksma C.J., Howard E.W., Tomasek J.J. Myocardin-related transcription factors A and B are key regulators of TGF-beta1-induced fibroblast to myofibroblast differentiation. J Invest Dermatol 2011, 131:2378-2385.
85. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926.
86. Kikuta K., Masamune A., Watanabe T., Ariga H., Itoh H., Hamada S., Satoh K., Egawa S., Unno M., Shimosegawa T. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010, 403:380-384.
87. Rasanen K., Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010, 316:2713-2722.
88. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
89. Jiang L., Gonda T.A., Gamble M.V., Salas M., Seshan V., Tu S., Twaddell W.S., Hegyi P., Lazar G., Steele I., et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res 2008, 68:9900-9908.
90. Vizoso M., Esteller M. DNA methylation plasticity contributes to the natural history of metastasis. Cell Cycle 2015, 14:2863-2864.
91. Hanson J.A., Gillespie J.W., Grover A., Tangrea M.A., Chuaqui R.F., Emmert-Buck M.R., Tangrea J.A., Libutti S.K., Linehan W.M., Woodson K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006, 98:255-261.
92. Vizoso M., Puig M., Carmona F.J., Maqueda M., Velasquez A., Gomez A., Labernadie A., Lugo R., Gabasa M., Rigat-Brugarolas L.G., et al. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. Carcinogenesis 2015, 36:1453-1463.
93. Hu M., Yao J., Cai L., Bachman K.E., van den Brule F., Velculescu V., Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005, 37:899-905.
94. Berndt A., Kosmehl H., Mandel U., Gabler U., Luo X., Celeda D., Zardi L., Katenkamp D. TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995, 27:1014-1020.
95. Dugina V., Fontao L., Chaponnier C., Vasiliev J., Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci 2001, 114:3285-3296.
96. Webber J.P., Spary L.K., Sanders A.J., Chowdhury R., Jiang W.G., Steadman R., Wymant J., Jones A.T., Kynaston H., Mason M.D., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2015, 34:290-302.
97. Hinz B. The extracellular matrix and transforming growth factor-beta1: Tale of a strained relationship. Matrix Biol 2015, 47:54-65.
98. Kubow K.E., Klotzsch E., Smith M.L., Gourdon D., Little W.C., Vogel V. Crosslinking of cell-derived 3D scaffolds up-regulates the stretching and unfolding of new extracellular matrix assembled by reseeded cells. Integrative Biol 2009, 1:635-648.
99. Krammer A., Craig D., Thomas W.E., Schulten K., Vogel V. A structural model for force regulated integrin binding to fibronectin's RGD-synergy site. Matrix Biol 2002, 21:139-147.
100. Vogel V. Mechanotransduction involving multimodular proteins: converting force into biochemical signals. Annu Rev Biophys Biomol Struct 2006, 35:459-488.
101. Shinde A.V., Kelsh R., Peters J.H., Sekiguchi K., Van De Water L., McKeown-Longo P.J. The alpha4beta1 integrin and the EDA domain of fibronectin regulate a profibrotic phenotype in dermal fibroblasts. Matrix Biol 2015, 41:26-35.
102. Klingberg F., Chow M.L., Koehler A., Boo S., Buscemi L., Quinn T.M., Costell M., Alman B.A., Genot E., Hinz B. Prestress in the extracellular matrix sensitizes latent TGF-beta1 for activation. J Cell Biol 2014, 207:283-297.
103. Li B., Moshfegh C., Lin Z., Albuschies J., Vogel V. Mesenchymal stem cells exploit extracellular matrix as mechanotransducer. Sci Rep 2013, 3.
104. Freedman B.R., Bade N.D., Riggin C.N., Zhang S., Haines P.G., Ong K.L., Janmey P.A. The (dys)functional extracellular matrix. Biochim Biophys Acta 2015, 1853:3153-3164.
105. Wells R.G. The role of matrix stiffness in regulating cell behavior. Hepatology 2008, 47:1394-1400.
106. McLane J.S., Ligon L.A. Palladin mediates stiffness-induced fibroblast activation in the tumor microenvironment. Biophys J 2015, 109:249-264.
107. Chiquet M., Gelman L., Lutz R., Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta 2009, 1793:911-920.
108. Chiquet M., Renedo A.S., Huber F., Fluck M. How do fibroblasts translate mechanical signals into changes in extracellular matrix production?. Matrix Biol 2003, 22:73-80.
109. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
110. Chaudhuri O., Koshy S.T., Branco da Cunha C., Shin J.W., Verbeke C.S., Allison K.H., Mooney D.J. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. Nat Mater 2014, 13:970-978.
111. Hinz B., Gabbiani G., Chaponnier C. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol 2002, 157:657-663.
112. Ghosh K., Ingber D.E. Micromechanical control of cell and tissue development: implications for tissue engineering. Adv Drug Deliv Rev 2007, 59:1306-1318.
113. Balaban N.Q., Schwarz U.S., Riveline D., Goichberg P., Tzur G., Sabanay I., Mahalu D., Safran S., Bershadsky A., Addadi L., et al. Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates. Nat Cell Biol 2001, 3:466-472.
114. Geiger B., Bershadsky A., Pankov R., Yamada K.M. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2001, 2:793-805.
115. Geiger B., Bershadsky A. Assembly and mechanosensory function of focal contacts. Curr Opin Cell Biol 2001, 13:584-592.
116. Cao X., Lin Y., Driscoll T.P., Franco-Barraza J., Cukierman E., Mauck R.L., Shenoy V.B. A chemomechanical model of matrix and nuclear rigidity regulation of focal adhesion size. Biophys J 2015, 109:1807-1817.
117. Liu H., Radisky D.C., Wang F., Bissell M.J. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 2004, 164:603-612.
118. Akhtar N., Streuli C.H. Rac1 links integrin-mediated adhesion to the control of lactational differentiation in mammary epithelia. J Cell Biol 2006, 173:781-793.
119. Jou T.S., Nelson W.J. Effects of regulated expression of mutant RhoA and Rac1 small GTPases on the development of epithelial (MDCK) cell polarity. J Cell Biol 1998, 142:85-100.
120. Jaffe A.B., Hall A., Schmidt A. Association of CNK1 with Rho guanine nucleotide exchange factors controls signaling specificity downstream of Rho. Curr Biol 2005, 15:405-412.
121. Piersma B., de Rond S., Werker P.M.N., Boo S., Hinz B., van Beuge M.M., Bank R.A. YAP1 is a driver of myofibroblast differentiation in normal and diseased fibroblasts. Am J Pathol 2015, 185:3326-3337.
122. Lee H.-O., Mullins S.R., Franco-Barraza J., Valianou M., Cukierman E., Cheng J.D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245.
123. Rashid S.T., Humphries J.D., Byron A., Dhar A., Askari J.A., Selley J.N., Knight D., Goldin R.D., Thursz M., Humphries M. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res 2012.
124. Kii I., Nishiyama T., Li M., Matsumoto K., Saito M., Amizuka N., Kudo A. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 2010, 285:2028-2039.
125. Stromnes I.M., DelGiorno K.E., Greenberg P.D., Hingorani S.R. Stromal reengineering to treat pancreas cancer. Carcinogenesis 2014, 35:1451-1460.
126. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
127. Huang X., Yang N., Fiore V.F., Barker T.H., Sun Y., Morris S.W., Ding Q., Thannickal V.J., Zhou Y. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012, 47:340-348.
128. Carracedo S., Lu N., Popova S.N., Jonsson R., Eckes B., Gullberg D. The fibroblast integrin alpha11beta1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation. J Biol Chem 2010, 285:10434-10445.
129. Bredfeldt J.S., Liu Y., Conklin M.W., Keely P.J., Mackie T.R., Eliceiri K.W. Automated quantification of aligned collagen for human breast carcinoma prognosis. J Pathol Inform 2014, 5:28.
130. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 2011, 178:1221-1232.
131. Narani N., Arora P.D., Lew A., Luo L., Glogauer M., Ganss B., McCulloch C.A. Transforming growth factor-beta induction of alpha-smooth muscle actin is dependent on the deformability of the collagen matrix. Curr Top Pathol 1999, 93:47-60.
132. Chia H.N., Vigen M., Kasko A.M. Effect of substrate stiffness on pulmonary fibroblast activation by TGF-beta. Acta Biomater 2012, 8:2602-2611.
133. Hinz B., Mastrangelo D., Iselin C.E., Chaponnier C., Gabbiani G. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 2001, 159:1009-1020.
134. Tomasek J.J., Haaksma C.J., Eddy R.J., Vaughan M.B. Fibroblast contraction occurs on release of tension in attached collagen lattices: dependency on an organized actin cytoskeleton and serum. Anat Rec 1992, 232:359-368.
135. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
136. Bacac M., Provero P., Mayran N., Stehle J.C., Fusco C., Stamenkovic I. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One 2006, 1:e32.
137. Gupta V., Bassi D.E., Simons J.D., Devarajan K., Al-Saleem T., Uzzo R.G., Cukierman E. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 2011, 6:e21494.
138. Park J.H., McMillan D.C., Powell A.G., Richards C.H., Horgan P.G., Edwards J., Roxburgh C.S.D. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin Cancer Res 2015, 21:882-888.
139. Isella C., Terrasi A., Bellomo S.E., Petti C., Galatola G., Muratore A., Mellano A., Senetta R., Cassenti A., Sonetto C., et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015.
140. Goicoechea S.M., Garcia-Mata R., Staub J., Valdivia A., Sharek L., McCulloch C.G., Hwang R.F., Urrutia R., Yeh J.J., Kim H.J., et al. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene 2014, 33:1265-1273.
141. Bijlsma M.F., van Laarhoven H.W. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 2015, 34:97-114.
142. Cukierman E. Stromagenesis. Encyclopedia of Cancer 2009, Vol. 4:2843-2845. Springer. edn 2nd.
143. Stoker M.G., Shearer M., O'Neill C. Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts. J Cell Sci 1966, 1:297-310.
144. Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S., Loda M., Mahmood U., Ramaswamy S. Systems-level modeling of cancer-fibroblast interaction. PLoS One 2009, 4:e6888.
145. Vonlaufen A., Joshi S., Qu C., Phillips P.A., Xu Z., Parker N.R., Toi C.S., Pirola R.C., Wilson J.S., Goldstein D., et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008, 68:2085-2093.
146. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
147. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
148. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008, 14:5995-6004.
149. Mills L.D., Zhang Y., Marler R.J., Herreros-Villanueva M., Zhang L., Almada L.L., Couch F., Wetmore C., Pasca di Magliano M., Fernandez-Zapico M.E. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem 2013, 288:11786-11794.
150. Feldmann G., Habbe N., Dhara S., Bisht S., Alvarez H., Fendrich V., Beaty R., Mullendore M., Karikari C., Bardeesy N., et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57:1420-1430.
151. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., Koorstra J.B., Habbe N., Karikari C., Mullendore M., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008, 7:2725-2735.
152. Feig C., Jones J.O., Kraman M., Wells R.J., Deonarine A., Chan D.S., Connell C.M., Roberts E.W., Zhao Q., Caballero O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013, 110:20212-20217.
153. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
154. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
155. Toole B.P., Ghatak S., Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 2008, 9:249-252.
156. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
157. Evanko S.P., Potter-Perigo S., Petty L.J., Workman G.A., Wight T.N. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF-beta1 induction of lung myofibroblasts. Matrix Biol 2015, 42:74-92.
158. Chauhan V.P., Boucher Y., Ferrone C.R., Roberge S., Martin J.D., Stylianopoulos T., Bardeesy N., DePinho R.A., Padera T.P., Munn L.L., et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 2014, 26:14-15.
159. Hingorani S.R., Harris W.P., Beck J.T., Berdov B.A., Wagner S.A., Pshevlotsky E.M., Tjulandin S.A., Gladkov O.A., Holcombe R.F., Korn R., et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res 2016.
160. Dekker T.J., Charehbili A., Smit V.T., Ten Dijke P., Kranenbarg E.M., van de Velde C.J., Nortier J.W., Tollenaar R.A., Mesker W.E., Kroep J.R. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Mol Oncol 2015, 9:1120-1128.
161. Connolly E.C., Freimuth J., Akhurst R.J. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012, 8:964-978.
162. Neuzillet C., Tijeras-Raballand A., Cohen R., Cros J., Faivre S., Raymond E., de Gramont A. Targeting the TGFβ pathway for cancer therapy. Pharmacol Therapeut 2015, 147:22-31.
163. Kelly M., Credill A.J.S. Nonclinical safety evaluation of a transforming growth factor β receptor I kinase inhibitor in fischer 344 rats and beagle dogs. J Clin Toxicol 2014, 04.
164. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., Balasubramaniam A., Nair S., Oliushine V., Parfenov V., et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13:132-142.
165. Jaschinski F., Rothhammer T., Jachimczak P., Seitz C., Schneider A., Schlingensiepen K.H. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Curr Pharm Biotechnol 2011, 12:2203-2213.
166. Schlingensiepen K.H., Jaschinski F., Lang S.A., Moser C., Geissler E.K., Schlitt H.J., Kielmanowicz M., Schneider A. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci 2011, 102:1193-1200.
167. Vallieres L. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. IDrugs 2009, 12:445-453.
168. Brandes A.A., Carpentier A.F., Kesari S., Sepulveda-Sanchez J.M., Wheeler H.R., Chinot O., Cher L., Steinbach J.P., Capper D., Specenier P., et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol 2016.
169. Fujiwara Y., Nokihara H., Yamada Y., Yamamoto N., Sunami K., Utsumi H., Asou H., Takahash I.O., Ogasawara K., Gueorguieva I., et al. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2015, 76:1143-1152.
170. Rodon J., Carducci M., Sepulveda-Sanchez J.M., Azaro A., Calvo E., Seoane J., Brana I., Sicart E., Gueorguieva I., Cleverly A., et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015, 33:357-370.
171. Herbertz S., Sawyer J.S., Stauber A.J., Gueorguieva I., Driscoll K.E., Estrem S.T., Cleverly A.L., Desaiah D., Guba S.C., Benhadji K.A., et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015, 9:4479-4499.
172. Serova M., Tijeras-Raballand A., Dos Santos C., Albuquerque M., Paradis V., Neuzillet C., Benhadji K.A., Raymond E., Faivre S., de Gramont A. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 2015, 6:21614-21627.
173. Ding N., Yu R.T., Subramaniam N., Sherman M.H., Wilson C., Rao R., Leblanc M., Coulter S., He M., Scott C., et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013, 153:601-613.
174. Bhattacharjee V., Zhou Y., Yen T.J. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014, 13:3839-3856.
175. Zhang Z., Yu X., Fang X., Liang A., Yu Z., Gu P., Zeng Y., He J., Zhu H., Li S., et al. Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis. Scientific Reports 2015, 5:17638.
176. Sherman M.H., Yu R.T., Engle D.D., Ding N., Atkins A.R., Tiriac H., Collisson E.A., Connor F., Van Dyke T., Kozlov S., et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014, 159:80-93.
177. Manson J.E., Bassuk S.S., Lee I.M., Cook N.R., Albert M.A., Gordon D., Zaharris E., Macfadyen J.G., Danielson E., Lin J., et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012, 33:159-171.
178. Chung M., Lee J., Terasawa T., Lau J., Trikalinos T.A. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:827-838.
179. Boldogh I., Albrecht T., Porter D.D. Persistent viral infections. Medical Microbiology 1996, edn 4th. S. Baron (Ed.).
180. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl 2013, 1-51.
181. He X., Tian Y., Guo L., Ano T., Lux R., Zusman D.R., Shi W. In vitro communities derived from oral and gut microbial floras inhibit the growth of bacteria of foreign origins. Microb Ecol 2010, 60:665-676.
182. Larsson P.G., Forsum U. Bacterial vaginosis - a disturbed bacterial flora and treatment enigma. APMIS 2005, 113:305-316.
183. Francescone R., Hou V., Grivennikov S.I. Microbiome, inflammation, and cancer. Cancer J 2014, 20:181-189.
184. Bjarnsholt T., Ciofu O., Molin S., Givskov M., Hoiby N. Applying insights from biofilm biology to drug development - can a new approach be developed?. Nat Rev Drug Discov 2013, 12:791-808.
185. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M., Horvath L.B., Kuzevska I., Fairley C.K. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006, 193:1478-1486.